MicroRNA Expression Profiles for B Cell Malignancy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing B cell malignancies, such as Burkitt lymphoma and diffuse large B cell lymphoma, are challenging due to overlapping morphologies and genetic similarities, leading to misclassification and inappropriate treatments, highlighting the need for more accurate diagnostic tools.
Innovation Solution
The use of microRNA expression profiles, specifically identifying and analyzing microRNAs like miR-223, miR-9, and miR-30, to differentiate between B cell malignancies by determining their levels in patient samples compared to control samples, utilizing microarray probes and real-time PCR for accurate diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional morphology-based methods are used to diagnose B cell malignancies, then the diagnostic process is simple and quick, but the accuracy is low due to overlapping morphologies and genetic similarities between different malignancies
Solution Approach 1:
The patent shifts the diagnostic parameters from morphological features (shape, size, structure) to molecular expression profiles (microRNA levels). By measuring the expression levels of specific microRNAs like miR-223, miR-9, and miR-30, the method achieves higher diagnostic accuracy by detecting molecular differences that are not visible through conventional morphology-based approaches.
Solution Approach 2:
The patent introduces microRNA expression profiling as an intermediary diagnostic tool between conventional morphology-based methods and molecular genetics. This intermediary approach uses microarrays or real-time PCR to measure microRNA levels, providing a bridge that offers higher accuracy than morphology while being more accessible than full genomic sequencing.
2Measurement precision
If microRNA expression profiling is used to improve diagnostic accuracy, then the precision of malignancy identification increases, but the complexity of the diagnostic procedure increases
Solution Approach 1:
The patent extracts and measures specific microRNA molecules (miR-223, miR-9, miR-30) from patient samples using targeted approaches. By focusing on a limited set of specific microRNAs rather than analyzing the entire transcriptome, the method achieves high precision while reducing the complexity of detection compared to comprehensive molecular profiling.
3Reliability
If conventional morphology-based diagnosis is used, then the diagnostic process is fast and simple, but misclassification occurs leading to inappropriate treatments
Solution Approach 1:
The patent changes the diagnostic parameters from visible morphological characteristics to molecular expression levels of microRNAs. This parameter shift enables more reliable differentiation between B cell malignancies by detecting molecular signatures that are not apparent through conventional morphology, thereby reducing misclassification and improving treatment selection.
Data Source
AI summary
Disclosed are nucleic acid sequences, including microRNA sequences and cDNA sequences, as well as vectors, DNA libraries, microarrays, and recombinant cells comprising the nucleic acid sequences described herein. Methods of determining the B cell stage from which a B cell malignancy is derived. Methods of identifying B cell malignancies are also provided. Methods of diagnosing B cell malignancies are provided. Such methods comprise, in certain embodiments, detecting one or more microRNAs or cDNAs as disclosed herein.